Keymed Biosciences Inc.
http://www.keymedbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Keymed Biosciences Inc.
Chinese Domestic Alliances Focus On China-Only Rights As Confidence Grows
Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.
ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
Watch Out Sanofi! Chinese Fast-Follower Emerges With Dupixent Rival
Keymed’s anti-IL-4Rα antibody stapokibart has delivered compelling top-line efficacy and safety results in a China Phase III study, which could help it challenge Sanofi/Regeneron’s Dupixent in the country.
ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Technologies
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Keymed Bioscience (Chengdu) Co., Ltd.
- Chengdu Keymed
- 2Health Biosciences Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice